Intranasal delivery of a polymeric nanoparticle subunit vaccine for the induction of protective immunity against respiratory syncytial virus - Report - MDSpire
Advertisement
Intranasal delivery of a polymeric nanoparticle subunit vaccine for the induction of protective immunity against respiratory syncytial virus
Clinical Report: Intranasal Administration of a Nanoparticle-Based Subunit Vaccine
Overview
This study presents an intranasal subunit vaccine, PreF-bNP, designed to elicit protective immunity against respiratory syncytial virus (RSV) in young preimmune mice. The vaccine demonstrated significant immunogenicity.
Background
Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections in children under five, leading to significant morbidity and mortality. Current preventive measures, including maternal vaccination and monoclonal antibodies, offer limited duration of protection.
Data Highlights
No numerical data or trial data presented in the article.
Key Findings
Intranasal administration of PreF-bNP increased IL-12+ dendritic cells in a preimmune RSV mouse model.
The vaccine generated Th1-polarized CD4 effector and tissue resident memory T cells (TRMs).
Antiviral CD8 TRMs were established in the lung following immunization.
Immunization with PreF-bNP resulted in reduced mucus production in the lungs.
Clinical Implications
The findings indicate that the intranasal PreF-bNP vaccine warrants further investigation for its safety and immune response in pediatric populations.
Conclusion
The intranasal PreF-bNP vaccine warrants further investigation.
